Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy

Recruiting
50 years - 69 years
All
Phase 4
818 participants needed
1 Location

Brief description of study.

Study to evaluate the efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Colorectal Cancer Early Detection
  • Age: 50 years - 69 years
  • Gender: All

Inclusion Criteria:

  1. Men and women aged 50 to 69.
  2. Have participated in the early detection program for colorectal cancer.
  3. Positive result in the fecal occult blood test (≥20 μg Hb/g feces).
  4. Scheduled screening colonoscopy at Hospital Clínic de Barcelona.
  5. Signed informed consent form.

Exclusion Criteria:

  1. Severe renal failure (grade IV or V) (Annex 6, Stages of Renal Impairment) and/or congestive heart failure (New York Heart Association Scale Class III and IV) (Annex 7, NYHA Scale).
  2. Colonoscopy within the last year.
  3. Barthel Index of <20 (Annex 5, Barthel Index) and who also meet the Rome IV Criteria for the diagnosis of functional constipation (Annex 8, Rome IV Criteria).
  4. Mental disability or severe mental disorder (schizophrenia and other psychotic disorders, recurrent severe major depressive disorders, severe obsessive-compulsive disorder, severe personality disorders, and bipolar disorders).
  5. Do not understand spoken or written Catalan or Spanish.
  6. Partial or total colon resection.
  7. Personal history of CRC or colorectal pathology that requires specific follow-up (ulcerative colitis, Crohn's disease, or colorectal adenomas).
  8. Terminal illness or serious illness/disability that contraindicates subsequent colon study.
  9. Gastrointestinal disorders that contraindicate the use of study products (gastric emptying disorders, gastrointestinal perforation or obstruction, ileus, toxic megacolon).
  10. Hypermagnesemia.
  11. Rhabdomyolysis.
  12. Phenylketonuria.
  13. Glucose-6-phosphate dehydrogenase deficiency.
  14. Hypersensitivity to the active ingredients of excipients.
  15. Pregnancy or breastfeeding.

Updated on 06 Jul 2026. Study ID: 2025-523748-11-00

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Please provide your preferred way of contact1234
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team